241 related articles for article (PubMed ID: 33615806)
1. Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
Liu Z; Chen Y; Wei Z; He Y; Wang J; Mu X; He L; Li R; Hu X; Peng X
Ann Palliat Med; 2021 Mar; 10(3):2805-2814. PubMed ID: 33615806
[TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
[TBL] [Abstract][Full Text] [Related]
4. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
5. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
[TBL] [Abstract][Full Text] [Related]
6. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Hahn AW; Klaassen Z; Agarwal N; Haaland B; Esther J; Ye XY; Wang X; Pal SK; Wallis CJD
Eur Urol Oncol; 2019 Nov; 2(6):708-715. PubMed ID: 31588018
[TBL] [Abstract][Full Text] [Related]
7. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
Monteiro FSM; Soares A; Debiasi M; Schutz FA; Maluf FC; Bastos DA; Sasse A; Cauduro CGS; Mendes GO; Ziegelmann PK; Fay AP
Clin Genitourin Cancer; 2020 Aug; 18(4):244-251.e4. PubMed ID: 32303427
[TBL] [Abstract][Full Text] [Related]
8. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Lombardi P; Filetti M; Falcone R; Di Bidino R; Iacovelli R; Ciccarese C; Bria E; Tortora G; Scambia G; Daniele G
Cancer Treat Rev; 2022 May; 106():102377. PubMed ID: 35313232
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM
Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
Mori K; Mostafaei H; Miura N; Karakiewicz PI; Luzzago S; Schmidinger M; Bruchbacher A; Pradere B; Egawa S; Shariat SF
Cancer Immunol Immunother; 2021 Feb; 70(2):265-273. PubMed ID: 32757054
[TBL] [Abstract][Full Text] [Related]
11. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis.
Quhal F; Mori K; Remzi M; Fajkovic H; Shariat SF; Schmidinger M
Curr Opin Urol; 2021 Jul; 31(4):332-339. PubMed ID: 33965978
[TBL] [Abstract][Full Text] [Related]
13. First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Rousseau B; Kempf E; Desamericq G; Boissier E; Chaubet-Houdu M; Joly C; Saldana C; Boussion H; Neuzillet C; Macquin-Mavier I; Oudard S; Salomon L; de la Taille A; Tournigand C
Crit Rev Oncol Hematol; 2016 Nov; 107():44-53. PubMed ID: 27823651
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
Chau V; Bilusic M
Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
[TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Wang S; Lv H; Yu J; Chen M
Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
[TBL] [Abstract][Full Text] [Related]
16. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma.
Riaz IB; He H; Ryu AJ; Siddiqi R; Naqvi SAA; Yao Y; Husnain M; Narasimhulu DM; Mathew J; Sipra QUAR; Vandvik PO; Joseph RW; Liu H; Wang Z; Herasevich V; Singh P; Hussain SA; Ho TH; Bryce AH; Pagliaro LC; Murad MH; Costello BA
Eur Urol; 2021 Dec; 80(6):712-723. PubMed ID: 33824031
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
Krawczyk K; Śladowska K; Holko P; Kawalec P
Front Pharmacol; 2023; 14():1223929. PubMed ID: 37745049
[No Abstract] [Full Text] [Related]
19. Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
Nocera L; Karakiewicz PI; Wenzel M; Tian Z; Shariat SF; Saad F; Chun FKH; Briganti A; Kapoor A; Lalani AK
J Urol; 2022 Jan; 207(1):16-24. PubMed ID: 34546767
[TBL] [Abstract][Full Text] [Related]
20. Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis.
Satkunasivam R; Guzman JC; Klaassen Z; Hall ME; Luckenbaugh AN; Lim K; Laviana AA; DeRosa AP; Beckermann KE; Rini B; Wallis CJ
Urol Oncol; 2022 Feb; 40(2):64.e17-64.e24. PubMed ID: 34690032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
